These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Lee JK; Hong YJ; Han CJ; Hwang DY; Hong SI Int J Oncol; 2000 Jul; 17(1):149-52. PubMed ID: 10853032 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373 [TBL] [Abstract][Full Text] [Related]
7. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Amirkhosravi A; Amaya M; Siddiqui F; Biggerstaff JP; Meyer TV; Francis JL Platelets; 1999; 10(5):285-92. PubMed ID: 16801104 [TBL] [Abstract][Full Text] [Related]
9. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome. Stalmans I Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Adams J; Carder PJ; Downey S; Forbes MA; MacLennan K; Allgar V; Kaufman S; Hallam S; Bicknell R; Walker JJ; Cairnduff F; Selby PJ; Perren TJ; Lansdown M; Banks RE Cancer Res; 2000 Jun; 60(11):2898-905. PubMed ID: 10850435 [TBL] [Abstract][Full Text] [Related]
11. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Hicklin DJ; Ellis LM J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754 [TBL] [Abstract][Full Text] [Related]
13. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638 [TBL] [Abstract][Full Text] [Related]
14. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Balsari A; Maier JA; Colnaghi MI; Ménard S Lab Invest; 1999 Jul; 79(7):897-902. PubMed ID: 10418830 [TBL] [Abstract][Full Text] [Related]
15. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548 [TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021 [TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
19. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? George ML; Eccles SA; Tutton MG; Abulafi AM; Swift RI Clin Cancer Res; 2000 Aug; 6(8):3147-52. PubMed ID: 10955796 [TBL] [Abstract][Full Text] [Related]
20. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]